{"context":{"query":">>mondo>>clinical_trials","source_dataset":"mondo","target_dataset":"clinical_trials"},"stats":{"queried":1,"total":100,"mapped":1},"pagination":{"has_next":true,"next_token":"-1[]MONDO:0005180,73,MONDO:0005180,175,0]["},"schema":"id|brief_title|overall_status|phase|study_type","mappings":[{"input":"MONDO:0005180","source":"MONDO:0005180|Parkinson disease","targets":["NCT00001520|The Early Reversibility of Rocuronium After Different Doses of Neostigmine|COMPLETED|PHASE4|INTERVENTIONAL","NCT00030979|Donepezil to Treat Dementia in Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT00043849|Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)|COMPLETED|PHASE4|INTERVENTIONAL","NCT00095810|Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT00125567|Stalevo in Early Wearing-Off Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT00143026|Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States|COMPLETED|PHASE4|INTERVENTIONAL","NCT00144300|Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT00153972|Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT00174239|Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.|TERMINATED|PHASE4|INTERVENTIONAL","NCT00215904|D-serine Adjuvant Treatment for Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT00247247|Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off.|COMPLETED|PHASE4|INTERVENTIONAL","NCT00272688|Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit|COMPLETED|PHASE4|INTERVENTIONAL","NCT00297778|Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms|COMPLETED|PHASE4|INTERVENTIONAL","NCT00304161|Effectiveness of Antidepressant Treatment for Depression in People With Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT00307450|Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT00321854|Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)|COMPLETED|PHASE4|INTERVENTIONAL","NCT00354133|Controlled Trial With Deep Brain Stimulation in Patients With Early Parkinson's Disease|UNKNOWN|PHASE4|INTERVENTIONAL","NCT00373087|COMT Polymorphism and Entacapone Efficacy|COMPLETED|PHASE4|INTERVENTIONAL","NCT00391898|Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off|COMPLETED|PHASE4|INTERVENTIONAL","NCT00399477|A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT00402233|A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT00437125|Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT00443872|Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists|COMPLETED|PHASE4|INTERVENTIONAL","NCT00455143|Cognitive Protection - Dexmedetomidine and Cognitive Reserve|TERMINATED|PHASE4|INTERVENTIONAL","NCT00462007|Study to Evaluate Initiation of Stalevo in Early Wearing-off|COMPLETED|PHASE4|INTERVENTIONAL","NCT00462254|Ramelteon (ROZEREM) in the Treatment of Sleep Disturbances Associated With Parkinson's Disease|TERMINATED|PHASE4|INTERVENTIONAL","NCT00477802|Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease|TERMINATED|PHASE4|INTERVENTIONAL","NCT00485069|REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study|COMPLETED|PHASE4|INTERVENTIONAL","NCT00489255|Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment|COMPLETED|PHASE4|INTERVENTIONAL","NCT00526630|Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT00561678|Perioperative Cognitive Function - Dexmedetomidine and Cognitive Reserve|COMPLETED|PHASE4|INTERVENTIONAL","NCT00571285|Clinical Effects of Vitamin D Repletion in Patients With Parkinson's Disease|TERMINATED|PHASE4|INTERVENTIONAL","NCT00584025|Keppra IV for the Treatment of Motor Fluctuations in Parkinson's Disease|WITHDRAWN|PHASE4|INTERVENTIONAL","NCT00584090|Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease|WITHDRAWN|PHASE4|INTERVENTIONAL","NCT00590122|Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study|COMPLETED|PHASE4|INTERVENTIONAL","NCT00594464|A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery|COMPLETED|PHASE4|INTERVENTIONAL","NCT00601978|Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off|WITHDRAWN|PHASE4|INTERVENTIONAL","NCT00632762|Long-Term Effects of Amantadine in Parkinsonian (AMANDYSK)|COMPLETED|PHASE4|INTERVENTIONAL","NCT00640159|Selegiline to Zelapar Switch Study in Parkinson Disease Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT00642356|Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off|TERMINATED|PHASE4|INTERVENTIONAL","NCT00646204|Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT00696215|The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease|UNKNOWN|PHASE4|INTERVENTIONAL","NCT00755027|Rasagiline and Apathy in Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT00806468|Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease|TERMINATED|PHASE4|INTERVENTIONAL","NCT00822913|Botulinum A Toxin in Patients With Parkinson's Disease|UNKNOWN|PHASE4|INTERVENTIONAL","NCT00888186|Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics|COMPLETED|PHASE4|INTERVENTIONAL","NCT00906828|Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors|COMPLETED|PHASE4|INTERVENTIONAL","NCT00908076|Amitiza in Constipation Associated With PD (Parkinson's Disease)|COMPLETED|PHASE4|INTERVENTIONAL","NCT00914095|Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease (PARKGAIT-II)|COMPLETED|PHASE4|INTERVENTIONAL","NCT00914134|Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT00986245|Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily|COMPLETED|PHASE4|INTERVENTIONAL","NCT00998660|RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR)|COMPLETED|PHASE4|INTERVENTIONAL","NCT01007630|A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients|UNKNOWN|PHASE4|INTERVENTIONAL","NCT01048229|Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease|TERMINATED|PHASE4|INTERVENTIONAL","NCT01049984|Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT01052831|Naltrexone for Impulse Control Disorders in Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT01055379|Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn|COMPLETED|PHASE4|INTERVENTIONAL","NCT01071395|Validation of Dyskinesia Rating Scales|COMPLETED|PHASE4|INTERVENTIONAL","NCT01108029|Study of Memantine for Gait Disorders And Attention Deficit In Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT01168596|Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT01178047|Multicenter Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's Disease|TERMINATED|PHASE4|INTERVENTIONAL","NCT01216904|Nicotine Treatment of Impulsivity in Parkinson's Disease|UNKNOWN|PHASE4|INTERVENTIONAL","NCT01244269|The Effect of Methylphenidate on Non-motor Symptoms and Postural Control in Parkinson's Disease.|TERMINATED|PHASE4|INTERVENTIONAL","NCT01300819|Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms|COMPLETED|PHASE4|INTERVENTIONAL","NCT01313819|The Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy|UNKNOWN|PHASE4|INTERVENTIONAL","NCT01313845|Effect of Intravenous Amantadine on Gait Freezing in Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT01340885|Cognitive Decline in Non-demented PD|COMPLETED|PHASE4|INTERVENTIONAL","NCT01382342|The Effect of Rasagiline on Cognition in Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT01385735|Emotion, Mood and Executive Function in Parkinson's Disease (PD)|UNKNOWN|PHASE4|INTERVENTIONAL","NCT01421719|Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT01485172|A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT01494532|A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT01497652|A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy|COMPLETED|PHASE4|INTERVENTIONAL","NCT01515774|Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID)|UNKNOWN|PHASE4|INTERVENTIONAL","NCT01519271|Mild Cognitive Impairment in Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT01521117|The Effect of Donepezil on Gait and Balance in Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT01523301|Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT01662414|Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT01673724|Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT01721460|Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus|COMPLETED|PHASE4|INTERVENTIONAL","NCT01723228|Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT01733199|Behavioural Addictions Occurring During a Dopaminergic Treatment Prescribe Under Parkinson's Disease: Study of the Psychopathological, Neurological, Pharmacokinetic and Genetic Profiles|COMPLETED|PHASE4|INTERVENTIONAL","NCT01770145|Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)|COMPLETED|PHASE4|INTERVENTIONAL","NCT01780467|Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients|UNKNOWN|PHASE4|INTERVENTIONAL","NCT01782222|Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy|COMPLETED|PHASE4|INTERVENTIONAL","NCT01782638|Effect of Deep Brain Stimulation on Gait of Patients With Parkinson's Disease Depending on Electrode Location in Subthalamic Area|COMPLETED|PHASE4|INTERVENTIONAL","NCT01807481|Phase IV Study to Evaluate the Efficacy and Safety of Mircera in PD|UNKNOWN|PHASE4|INTERVENTIONAL","NCT01856738|Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease|TERMINATED|PHASE4|INTERVENTIONAL","NCT02225548|Sagene 2014 - Parkinson's Disease and Erectile Dysfunction|UNKNOWN|PHASE4|INTERVENTIONAL","NCT02231905|Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT02233023|Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT02256319|Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity Measured Through Implanted Stimulators|COMPLETED|PHASE4|INTERVENTIONAL","NCT02365870|Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment|TERMINATED|PHASE4|INTERVENTIONAL","NCT02385500|Fesoterodine on Urgency Episodes in Parkinson's Disease Population|TERMINATED|PHASE4|INTERVENTIONAL","NCT02472210|The Use of Botox in Advanced Parkinson's Patients Experiencing Pain|UNKNOWN|PHASE4|INTERVENTIONAL","NCT02473562|Varenicline Treatment for Excessive Daytime Sleepiness in Parkinson's Disease|TERMINATED|PHASE4|INTERVENTIONAL","NCT02480803|INfusion VErsus STimulation in Parkinson's Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT02536976|Mirabegron in Parkinson Disease and Impaired Cognition|COMPLETED|PHASE4|INTERVENTIONAL","NCT02549573|Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®|TERMINATED|PHASE4|INTERVENTIONAL","NCT02670161|Quality Improvement and Practice Based Research in Neurology Using the EMR|ENROLLING_BY_INVITATION|PHASE4|INTERVENTIONAL"]}]}